Philippe Aftimos, MD

Rotterdam citytrip and Union Saint-Gilloise 💛💙 at De Kuip

🚂☀️🚤🏟️

I am a big fan of @fontainesdc.bsky.social and I discovered their partnership with @bfcdublin.bsky.social at Rock Werchter. I immediately loved the club’s vibes. And that third jersey, wow 🤩

Rock Werchter 2025

#RW25

I reviewed for @myesmo.bsky.social new data with a potential clinical impact in HR+/HER2- metastatic breast cancer 👇

#ESMOMembers – vote for the leaders who will shape ESMO’s future. Vote now for the Directors of Education, Public Policy & Membership - and the Chair and members of the Nomination Committee.

📽️ Watch the ESMO President’s message

🔗 Vote now: ow.ly/H7UK50VZR0X

Cool simultaneous illustration of my talk at the seminar series organised by Institut Jules Bordet to celebrate Clinical Trials Day

🇩🇪 🚆 🇧🇪 🚌 🏟️ ⚽️💛💙

@hoperugo.bsky.social is discussing the results of the ROSALINE trial, an IIT sponsored by the Institut Jules Bordet that evaluated ROS1 inhibition with neo-adj endocrine therapy in early ILBC #ESMOBreast25 👏🏻 @aftimosp.bsky.social & Soraia Lobo-Martins

Day 2 of #ESMOBreast25 in Munich.

Data on ADCs will be presented during Mini Oral session 1 including results on 2️⃣ novel ADCs targeting B7H4 in HR+/HER2- and TNBC:

emiltatug ledadotin and puxitatug samrotecan

#ESMOAmbassadors @myesmo.bsky.social

Part of the Institut Jules Bordet breast cancer team at #ESMOBreast25

@laubdh.bsky.social

In her Keynote Lecture at #ESMOBreast25, @loisher.bsky.social considers the question of who truly benefits from #immunotherapy in #BreastCancer, noting that success hinges on careful definition of responsive patient subgroups.

Full article in the #ESMODailyReporter

🔗 ow.ly/rtbo50VSyiN

#ESMOBreast25 Award recipient, Gabriel Hortobagyi, describes the long journey that has led to targeted #BreastCancer therapies and explains how patient involvement is central to advancing research.

Read more in the #ESMODailyReporter

🔗 ow.ly/kqju50VSpOE

At #ESMOBreast25, refinements in #LiquidBiopsy use are reviewed, including a defined window for ESR1 mutation detection in metastatic #BreastCancer and use of pre-neoadjuvant treatment #ctDNA levels to predict recurrence.

More in the #ESMODailyReporter

🔗 ow.ly/R93050VSChg

The path forward for immunotherapy biomarkers in breast cancer by @marleenkok.bsky.social

#ESMOBreast25 #ESMOAmbassadors @myesmo.bsky.social

An enthusiast and militant talk by @marleenkok.bsky.social at #ESMOBreast25 on the importance of studying biomarkers for immunotherapy in breast cancer, highlighting the KN522 example

#ESMOAmbassadors @myesmo.bsky.social

#ESMOBreast25 @laubdh.bsky.social from Institut Jules Bordet on the role of immunotherapy in ER+/HER2- early breast cancer #ESMOAmbassadors @myesmo.bsky.social

Sustainable travel 🚆 🌱 🌎 to Munich 🇩🇪 and #ESMOBreast25

#ESMOAmbassadors

@myesmo.bsky.social

@aftimosp.bsky.social @erikahamilton9.bsky.social @marleenkok.bsky.social @ptarantinomd.bsky.social

#ESMOBreast25: Do not miss the latest research findings in #BreastCancer brought to you by the #ESMOAmbassadors & become part of the conversation. #bcsm
🔗 ow.ly/VtAE50VP4Jf

03/05/2025
💛💙

#USGGNK

Floralia Brussels 2025 🌷

floralia-brussels.be/en

🚀 ESMO is now on Bluesky

This is not an April Fools' announcement, nor is it an AI-generated post. ESMO is launching on Bluesky with a poll on AI to start the conversation.

Join us for the latest in oncology education and information.

#AIOncology #HealthAI #ESMOAI25

Newly published ESMO recommendations provide roadmap for the implementation of molecular tumour boards in clinical practice.
Discover the key focus areas to optimise #PrecisionOncology
Read via #ESMODailyReporter: ow.ly/uQGA50Vvu4j
@benwestphalen.bsky.social

📣#ESMOBreast25: Regular abstract titles and authors are online! Check the programme to see the exciting studies you will have the chance to see at this event.
⏰And if you register by 17 April, you can benefit from advantageous rates!

🔗 buff.ly/9Ply77K

So many interesting discussions with very bright 💡 people!

What an outstanding summit organized by SOLTI. Key overview on the Lobular BC: current clinical research, pathological characterization and imaging and focus on big alliances to move forward on the field.
#uptodatesummit #beSOLTI

L’Union n’a pas besoin d’être champion (mais on le sera)